|Referral date||01 December 2007|
|Closing date for invited submissions / evidence submission:||TBC|
|1st appraisal committee meeting:||TBC|
|2nd appraisal committee meeting||TBC|
|Communications manager:||Sarita Tamber|
|Executive Lead:||Gillian Leng|
|Project manager:||Bijal Joshi|
|Technical Lead:||Scott Goulden|
|10 August 2009||
Further to the Scoping Workshop, lapatinib for the first-line treatment of metastatic hormone-sensitive breast cancer has been temporarily suspended.
Following discussion of the comments received during the scoping exercises/workshop, we are liaising with the Department of Health for confirmation that lapatinib is appraised alongside trastuzumab, in a Multiple Technology Appraisal.
When further details are available, the website will be updated.
For further information on how we develop guidance, please see our page about NICE technology appraisal guidance